IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Trial details
- Registry ID
- NCT05742607
- Drugs studied
- IPH5201 + durvalumab + standard chemotherapy
TrialRedline tracks 3 clinical trials sponsored by Innate Pharma: 3 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)NCT05742607 | IPH5201 + durvalumab + standard chemotherapy | Recruiting | 2027-06Estimated |
| IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell LymphomaNCT03902184 | IPH4102 | Completed | 2026-01-08Actual |
| Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple MyelomaNCT01222286 | IPH2101 | Completed | 2012-07Actual |
Names as written in the registry records.
NCT05742607 · Innate Pharma
Before: Jun 2025. After: Jun 2027.
NCT03902184 · Innate Pharma
Before: 31 Oct 2023. After: 8 Jan 2026.
Before: Active not recruiting. After: Completed.